期刊文献+

乳腺癌中C-erbB-2、ER和PR表达及意义 被引量:7

Expression of C-erbB-2?ER and PR in Primary Breast Carcinoma and Its Clinical Significance
在线阅读 下载PDF
导出
摘要 目的分析研究C-erbB-2、ER、PR在乳腺癌中的表达与转移及预后关系。方法用免疫组化法测定93例原发性乳腺癌C-erbB-2、ER、PR的表达情况。结果C-erbB-2、ER、PR阳性表达率分别为:40.9%(38/93)、47.3%(44/93)、55.9%(52/93)。C-erbB-2随着临床分期增加和腋窝淋巴结转移数目的增加,其阳性表达率亦增加,差异有显者性(P<0.05)。ER、PR阳性表达率随着临床分期的递增和腋窝淋巴结转移数目的增加而降低,差异无显著性(P>0.05)。ER、PR阳性表达率与C-erbB-2阳性表达呈负相关,差异无显著性(P>0.05)。结论C-erbB-2是判断乳腺癌预后的有效指标,ER、PR与临床分期及腋窝淋巴结转移有一定关系,联合检测C-erbB-2、ER、PR可指导临床综合治疗。 Objective To investigate the expression of C-erbB-2?ER and PR and the relationships to the metastasis and prognosis of primary breast carcinoma. Methods The expression of C-erbB-2?ER and PR was detected by immunochemical s-p methods in 93 Cases of primary breast carcinoma. Results The expression of C-erbB-2?ER?PR were observed in 40.9%(38/93), 47.3%(44/93)?55.92%(52/93) respectively. The positive rates of C-erbB-2 increased with the number of metastasis lymph node and clinical stage, and there was a significant correlation(P<0.05).The positive rates of ER and PR decreased with the number of metastasis lymph node and clinical stage. and there wasn't significant correlation(P>0.05). ER and PR had a reverse correlation with the expression of C-erbB-2, but there wasn't significant difference(P>0.05). Conclusions The C-erbB-2 is an useful prognostic factor in patients with breast carcinoma. The expression of ER and PR is associated with the clinical stage and lymph node metastasis of breast carcinoma, but the correlativity isn't significant. The combined detection of C-erbB-2?ER and PR has important significance for clinical therapy.
出处 《实用全科医学》 2005年第4期301-302,共2页 Applied Journal Of General Practice
  • 相关文献

参考文献2

二级参考文献17

  • 1胡勇,饶慧蓉.癌基因c-erbB-2在乳腺癌研究中的进展[J].临床与实验病理学杂志,1993,9(4):298-301. 被引量:23
  • 2陈艺华.癌基因、抗癌基因异常与人乳腺癌[J].中华病理学杂志,1994,23(2):122-124. 被引量:12
  • 3郑德先.细胞凋亡的研究进展[J].中华病理学杂志,1996,25(1):50-53. 被引量:47
  • 4皋岚湘,丁华野,邓永江,吴霞,朱明华,田玉旺.乳腺癌多耐药基因产物的表达及其与预后因素的关系[J].诊断病理学杂志,1996,3(1):20-22. 被引量:4
  • 5Hudson LG, Ertl AP, Gill GN. Structure and inducible regulation of the human c-erbB-2/neu promoter [J]. J Biol Chem, 1990,265(3) :4389--4393.
  • 6Slamon DJ,Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer [J]. Science, 1989, 244 (4905):707 -712.
  • 7Gullic WJ. The role of the epidermal growth receptor and c-erbB-2 protein in breast cancer [J]. Int J Cancer, 1990,5(suppl) :55--61.
  • 8Yokoke T, Imaniura M, Teshima S, et al. c-erbB-2,p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study[J]. Anticamcer Res,1999,19(5B) :4007--4012.
  • 9Treurniet HF,Rookus MA, Peterse HL, et al. Differences in breast cancer risk factors to neu (c-erbB-2)protein overexpression of the breast tumor [J]. Cancer Res, 1992,52(8):2344--2345.
  • 10Woodburin JR. The epidermal growth factor receptor and its inhibition in cancer therapy [J]. Pharmacol Ther, 1999,82(2--3) :241--250.

共引文献40

同被引文献61

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部